Sharp Therapeutics Corp. (TSXV:SHRX)

Sharp Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	3.48	0.38	0.16
Cash & Short-Term Investments	3.48	0.38	0.16
Cash Growth	824.64%	129.45%	-
Prepaid Expenses	0.03	0.05	0.03
Total Current Assets	3.52	0.43	0.2
Property, Plant & Equipment	1.02	1.1	1.21
Other Long-Term Assets	0.02	0.02	0.02
Total Assets	4.55	1.55	1.42
Accounts Payable	0.27	0.18	0.1
Accrued Expenses	0.25	0.23	0.13
Current Portion of Long-Term Debt	-	7.28	3.94
Current Portion of Leases	0.04	0.03	0.03
Other Current Liabilities	0.13	-	-
Total Current Liabilities	0.69	7.72	4.2
Long-Term Debt	-	3.97	3.8
Long-Term Leases	1.28	1.32	1.34
Other Long-Term Liabilities	-	0.02	0.02
Total Liabilities	1.97	13.03	9.37
Common Stock	21.79	4.55	4.55
Additional Paid-In Capital	0.67	0.59	0.56
Retained Earnings	-19.89	-16.62	-13.06
Comprehensive Income & Other	0.01	-	-
Shareholders' Equity	2.58	-11.48	-7.95
Total Liabilities & Equity	4.55	1.55	1.42
Total Debt	1.32	12.6	9.11
Net Cash (Debt)	2.17	-12.22	-8.95
Net Cash Per Share	0.24	-2.81	-64.45
Filing Date Shares Outstanding	29.94	1.39	0.14
Total Common Shares Outstanding	28.22	1.39	0.14
Working Capital	2.83	-7.29	-4.01
Book Value Per Share	0.09	-8.25	-57.25
Tangible Book Value	2.58	-11.48	-7.95
Tangible Book Value Per Share	0.09	-8.25	-57.25
Machinery	0.2	0.19	0.18
Leasehold Improvements	0.01	0.01	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.